Our Approach
For Scientists
Our Approach
A comprehensive genomic analysis of each tumour
Every cancer is different. To better understand the biology of an individual patient's cancer, the Personalized OncoGenomics (POG) program combines whole-genome sequencing, transcriptome sequencing, clinical information, and expert interpretation.
Rather than examining only a predefined set of genes, POG takes a comprehensive approach to studying the tumour's genetic features. This can reveal a broad range of genomic changes and patterns of gene activity that may help explain how a cancer develops and behaves, and may help identify drugs to fight the cancer.
By bringing genomic and patient information together, POG aims to build a more complete picture of each tumour and identify potential opportunities to inform treatment and advance cancer research.
1. Starting with tumour and normal samples
Understanding what makes a tumour different
POG analyses tumour tissue alongside a matched normal sample, typically obtained from the patient's blood. Comparing these samples helps researchers distinguish changes acquired by the tumour from genetic variations that a person may have inherited.
Tumour tissue is carefully selected to ensure it contains sufficient cancer cells for analysis. DNA and RNA are then extracted from the selected tissue for genomic and transcriptomic sequencing.
Using matched samples provides important context for interpreting the molecular changes identified in a patient's cancer.
2. Sequencing the genome and transcriptome
Looking at both DNA and gene activity
POG uses two complementary approaches to study cancer:
Whole-genome sequencing (WGS) examines DNA across the genome to identify changes such as mutations, alterations in chromosome copy number, and structural rearrangements. These changes can provide clues about the genetic mechanisms involved in a tumour.
Transcriptome sequencing examines RNA, helping researchers understand which genes are active and how strongly they are expressed. It can also help identify gene fusions and other changes reflected in the tumour's RNA.
Together, these approaches provide information about both the DNA changes present in a tumour and how those changes may be reflected in its patterns of gene activity.
How is sequencing performed?
POG uses established laboratory workflows to prepare DNA and RNA for sequencing. Sequencing libraries are prepared and analysed using the Illumina NovaSeq X Plus platform.
Whole-genome sequencing targets approximately 100-fold coverage for tumour DNA and 40-fold coverage for matched normal DNA. These sequencing depths support the detection and interpretation of genomic alterations across the samples.
3. Analysing the tumour's molecular profile
Identifying genomic changes
POG uses specialized bioinformatics pipelines to analyse whole-genome sequencing data and identify different types of genomic alterations, including:
- Mutations: changes in individual DNA letters and small insertions or deletions.
- Copy-number alterations: gains or losses of sections of DNA.
- Structural variants: larger rearrangements of DNA within or between chromosomes.
- Gene fusions: events in which parts of different genes become joined.
These findings are compared with the patient's matched normal DNA to help identify alterations acquired by the tumour.
Understanding gene expression
Transcriptome data help researchers assess gene activity and identify genes that are expressed at unusually high or low levels.
These patterns can be compared with reference datasets to help identify features that may be relevant to the tumour's biology.
Bringing the findings together
The analysis extends beyond identifying individual alterations. POG combines genomic and transcriptomic findings to examine how different changes may relate to one another.
Specialized computational tools and curated genomic resources help identify affected genes, cancer-associated pathways, and patterns that may contribute to the development or behaviour of a tumour.
This integrated view provides the foundation for understanding the biological significance of a patient's cancer.
4. From genomic findings to biological meaning
Understanding why an alteration matters
Not all genomic alterations have the same significance. Some are well understood, while others may be less studied or have uncertain effects.
POG evaluates identified alterations in the context of established cancer biology, considering their potential effects on genes, proteins, and cellular pathways.
Rather than interpreting each finding in isolation, researchers consider how alterations and gene-expression patterns may work together to shape the tumour's molecular profile.
This helps build a more complete understanding of the biological processes that may be involved in an individual patient's cancer.
5. Evaluating potential therapeutic opportunities
Connecting molecular findings with available evidence
Some genomic alterations have known associations with treatments, while others may suggest possibilities that require further investigation.
POG evaluates findings for potential therapeutic relevance using an expert-curated knowledgebase developed at the Michael Smith Genome Sciences Centre. The knowledgebase brings together information from cancer and drug databases, clinical tests, and biomedical literature.
Researchers consider the available evidence when assessing whether an alteration may be relevant to a potential treatment.
Understanding the strength of the evidence
Evidence can vary considerably. It may include:
- Clinical evidence: findings from approved treatments, clinical trials, or other human studies.
- Preclinical evidence: research from laboratory experiments or model systems.
- Biological evidence: knowledge about the function of a gene, protein, or pathway and the possible effects of an alteration.
- Emerging evidence: early findings involving newer or less well-characterized alterations.
The relevance of each finding depends on the evidence available, the cancer type, and the broader molecular profile of the tumour.
What does this mean for patients?
POG may identify genomic findings that suggest potential therapeutic opportunities. However, not every alteration has a known treatment, and some findings may have limited or preliminary evidence.
POG's analysis is intended to support a deeper understanding of the tumour and potential treatment discussions with the patient's clinical team. A potential therapeutic association does not guarantee that a treatment will be available, appropriate, or effective for an individual patient.
6. Multidisciplinary interpretation
Understanding the tumour as a whole
The final interpretation brings together the genomic, transcriptomic, and clinical information available for each patient.
Experts in genomics, bioinformatics, and cancer biology review the tumour's molecular profile, considering potential driver alterations, affected pathways, gene-expression patterns, and the evidence supporting possible therapeutic associations.
Clinical information helps place these findings in the context of the patient's cancer and care.
From complex data to an integrated report
The findings are brought together in a patient-specific report describing the molecular features of the tumour, relevant biological insights, and potential therapeutic opportunities supported by the available evidence.
This multidisciplinary approach helps ensure that individual findings are considered as part of the broader picture of the tumour, rather than in isolation.
What makes POG different?
POG brings together several complementary elements to develop a comprehensive understanding of an individual patient's cancer:
- A broad view of the tumour: Whole-genome and transcriptome sequencing examine DNA changes and gene activity, rather than focusing only on a predefined set of genes.
- A patient-specific comparison: Matched tumour and normal samples help distinguish acquired cancer-related alterations from inherited genetic variation.
- Integrated analysis: Genomic findings, gene-expression patterns, biological pathways, and clinical information are considered together.
- Evidence-informed interpretation: Potential therapeutic associations are assessed using an expert-curated knowledgebase and the available scientific and clinical evidence.
- Multidisciplinary expertise: Specialists in genomics, bioinformatics, and cancer biology work together to interpret complex findings.
By combining these elements, POG aims to develop a detailed molecular picture of each tumour, support the exploration of potential treatment opportunities, and generate knowledge that can contribute to future cancer research.
An important note: POG is an exploratory research program. Its analyses may identify potential therapeutic opportunities, but they do not guarantee a treatment recommendation or a change in care. Treatment decisions remain the responsibility of the patient's clinical team, in discussion with the patient.